Katherine Liao

Associate Professor

Harvard Medical School

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Katherine Liao is an Associate Professor at Harvard Medical School in the United States. Her research focuses on chronic kidney disease, rheumatoid arthritis, and the application of artificial intelligence in treatment response studies. Recent articles include investigations into plasma proteomic profiles, high-sensitivity cardiac troponin in arthritis patients, and the socio-economic impact of rheumatic conditions on health outcomes.

Articles (23)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Christopher ODonnell

VP, Global Head, Cardiovascular and Metabolism Translational Medicine

Novartis

SWITZERLAND

View details

Priyam Das

Assistant Professor

Virginia Commonwealth University

UNITED STATES

View details

Olga Demler

Assistant Professor

Harvard University

UNITED STATES

View details

Rachel Knevel

UNITED KINGDOM

View details

Paul A. Welling

Johns Hopkins University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Katherine Liao

Research Interests

Explore related searches

Contact this professor

About

Articles (23)

Plasma Proteomic Profile of Dietary Potassium and Incident Chronic Kidney Disease

Characteristics Associated With Detectable High‐Sensitivity Cardiac Troponin in Patients With Rheumatoid Arthritis at Low‐Intermediate Cardiac Risk

Expanding Mechanistic Insights into Urinary Concentrating Ability

No association between vascular inflammation and estimated glomerular filtration rate in patients with rheumatoid arthritis: secondary analysis of the TARGET trial

Drs. Weber and Liao reply

Artificial intelligence as an assistant for studying treatment response in rheumatoid arthritis

Returning Incidental Research Findings from FDG PET/CT to Participants: A Survey of Investigators from a Clinical Trial of Rheumatoid Arthritis

The Association Between High-Sensitivity Cardiac Troponin T and Major Adverse Cardiovascular Events in Rheumatoid Arthritis

Classifying Individuals With Rheumatic Conditions as Financially Insecure Using Electronic Health Record Data and Natural Language Processing: Algorithm Derivation and Validation

Finding the Right Fit for Genes in Rheumatology Clinical Care

Association of the multi-biomarker disease activity score with arterial 18-fluorodeoxyglucose uptake in rheumatoid arthritis

Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial

Parkinson Disease Genetics Extended to African and Hispanic Ancestries in the VA Million Veteran Program

Social Determinants of Health Documentation Among Individuals With Rheumatic and Musculoskeletal Conditions in an Integrated Care Management Program

Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease

Sore, Hot, and at Risk: The Emerging Specialty of Cardio‐Rheumatology

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis

Natural Language Processing to Improve Prediction of Incident Atrial Fibrillation Using Electronic Health Records

B-Cell Targeted Therapeutics in Systemic Lupus Erythematosus: From Paradox to Synergy?

A Missense Variant in the IL-6 Receptor and Protection From Peripheral Artery Disease

Improving the Efficiency of Clinical Trial Recruitment Using an Ensemble Machine Learning to Assist With Eligibility Screening

Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial

Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis

Collaborators (5)

Christopher ODonnell

Priyam Das

Olga Demler

Rachel Knevel

Paul A. Welling

Make your next move.